Reviewer’s report

Title: Efficacy and safety of Myrrh in patients with incomplete abortion: a randomized, double-blind, placebo-controlled clinical study

Version: 1 Date: 13 Nov 2019

Reviewer: Emaediong Ibong Akpanekpo

Reviewer's report:

Introduction
You were able to:
- define incomplete abortion
- mentioned the treatment modalities: surgical, pharmacological and expectant management
- highlight the risks associated with surgical intervention and current pharmacological intervention
- highlighted the properties of Myrrh, composition, uses and mechanism of action
- highlighted the uterotonic properties of myrrh.

Materials and methods
Inclusion criteria
- Why was 20 weeks used as the gestational age for being included into the study?
- Is a thickened Endometrial Echo Complex diagnostic or definitive of incomplete abortion?
- What is the description of the 'endometrial mass consistent with RPOC”? What features did you use?
- When you say 'RPOC with an anterior-posterior diameter 15-50 mm in ultrasound imaging', what antero-posterior diameter are you measuring? That of the RPOC?
- Anterior-posterior diameter was selected between 15-50 mm, because previous clinical trials report favorable outcome after expectant management of RPOC in this range of size. Anterior-posterior diameter of what? If you used an AP diameter that favours expectant management of RPOC in 84% of cases (from your reference), how were you able to determine that the difference in the outcome of your intended intervention was not due to chance?

Randomization and study groups
- Did you use a computer program to generate the numbers? What is the name of this program?
- How was the sample size determined?

Plant material
- How did you determine the dose of Myrrh? Can you provide references?

Outcome measurements
- What were the expected side effects and how was it managed or prevented?
- What adverse events did you screen for?
- Did you measure the AP diameter of the endometrial cavity at the site of the suspected RPOC or did you measure the diameter of the r poc? Can you provide references to show that this measurement is an adequate measure or predictor of complete uterine evacuation?
Statistical analysis
- Were the residuals normally distributed prior to using the independent t test? What tests of normality did you use to ensure this?
- Did you test for homogeneity of variance? What test did you use?

Results
How did you evaluate the safety profile of Myrrh in this study?

Discussion
'Findings of the current study showed that the complete abortion rate was 82.9% for the intervention group.'
What was your outcome measure? What value of your outcome measure is suggestive of a 'complete abortion'?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Unable to assess

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal